Trials / Recruiting
RecruitingNCT06128252
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
A Prospective, Multicentre, Double-blind Randomized Controlled Clinical Study of the Efficacy and Safety of Taurine Combined With Serplulimab and Chemotherapy Versus Serplulimab Combined With Chemotherapy for Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- Tang-Du Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This project aims to evaluate the efficacy and safety of oral taurine supplementation combined with PD-1 inhibitor (serplulimab) and chemotherapy in inducing systemic CD8+ T cell responses and achieving improved gastric cancer patient outcomes than with serplulimab and chemotherapy alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Taurine | Taurine supplementation in tablets of 1.0 gram of taurine powder. Dosage: 3.0 gram/day. Frequency: 3 time/day. |
| BIOLOGICAL | Serplulimab | Serplulimab |
| DRUG | XELOX regimen | Oxaliplatin + capecitabine |
| DIETARY_SUPPLEMENT | Placebo | Taurine placebo in tablets of 1.0 gram of starch powder. Dosage: 3.0 gram/day. Frequency: 3 time/day. |
Timeline
- Start date
- 2024-09-01
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2023-11-13
- Last updated
- 2025-01-07
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06128252. Inclusion in this directory is not an endorsement.